vCLAS PMA pivotal data met endpoints; FDA approval decision determines whether cryoablation captures the refractory VT market

Bull

A positive PMA decision would validate the FULCRUM-VT results — 84.3% freedom from ICD shock at 6 months, 97.4% acute clinical success, and 2.4% major adverse events — as sufficient for market authorization, opening commercial access to a refractory VT population with few effective alternatives. Approval would also trigger milestone-based warrant exercises providing up to $31 million in additional proceeds, funding the commercial launch and next-generation vCLAS Ultra development.

Bear

The FDA could issue a complete response letter citing concerns about the durability of the 6-month efficacy endpoint, the absence of a randomized controlled comparator arm, or manufacturing and quality system deficiencies given Adagio's limited commercial-scale production history. A major device safety signal or adjudicated adverse event reanalysis during FDA review could also shift the risk-benefit calculus unfavorably, particularly given the high-risk patient population.